RE:RE:RE:RE:RE:MEDXF gets CRLDisagree. This is a canadian company so very few, especially US investors, really follow the story. The volume is next to nothing. The valuation is normally discounted to what a US company would trade at plus biotech is completely out of favor so even US companies who are actually getting FDA approval go down. My concern was that getting fda approval may not move this stock that much. Now, with a CRL, we are getting hammered. Earnings was verey disappointing last quarter but i think the stock held up because Ken was emphatic that they'd get fda approval so investors wanted to hold on. Now with the CRL, the stock is going to take a big tumble. They better deliver better numbers next quarter or ken will have ton of explaining to do. As it is, he will probably get an earful about the crl today. It would be nice if the company came out to say something. Ken had said mutliple times they fully expect approval, and even expanded approval for pediatric, based on their dialogue with the fda. what happened???